| Wissenschaftl. Titel | A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA 1/2) |
| Erkrankung |
Geschlechtsorgane:
Brustkrebs:
Zweitlinie oder höher
|
| Molekularer Marker |
HER2/neu neg. Triple neg (HER2/ER/PR neg) ER/PR neg. |
|
Agaplesion Markus Krankenhaus
(Geschlossen) PD Dr. med. Marc Thill Tel: 069 / 95332228 Fax: 069 / 95332733 marc.thill@fdk.info |
|
| Kurzprotokoll | Kurzprotokoll |
erstellt 18.02.2020 Student Studienregister
geändert 10.02.2022 Student Studienregister